{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vector&page=23",
    "query": {
      "condition": "Vector",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 687,
    "total_pages": 69,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vector&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vector&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T10:35:18.984Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00321061",
      "title": "Phase I Study of Vaccination Schedule of Experimental HIV Vaccines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "VRC-HIVDNA016-00, VRC-HIVADV014-00",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 60,
      "start_date": "2006-04-25",
      "completion_date": "2009-12-02",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-24T10:35:18.984Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00321061"
    },
    {
      "nct_id": "NCT01896102",
      "title": "A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Cerebral Adrenoleukodystrophy (CALD)"
      ],
      "interventions": [
        {
          "name": "Lenti-D Drug Product (eli-cel)",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Genetix Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "MALE",
        "summary": "Up to 17 Years · Male only"
      },
      "enrollment_count": 32,
      "start_date": "2013-08-21",
      "completion_date": "2021-03-26",
      "has_results": true,
      "last_update_posted_date": "2022-04-25",
      "last_synced_at": "2026-10-24T10:35:18.984Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01896102"
    },
    {
      "nct_id": "NCT07831473",
      "title": "Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Randomised Clinical Trial",
        "Double Blind",
        "Dengue",
        "Challenge Test",
        "Dose Escalation and Safety"
      ],
      "interventions": [
        {
          "name": "VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ALFQ adjuvant + Saline",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rDEN3Delta30",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "VLP Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 42,
      "start_date": "2027-01-04",
      "completion_date": "2028-05-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-10-24T10:35:18.984Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07831473"
    },
    {
      "nct_id": "NCT02751294",
      "title": "A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria, Vivax"
      ],
      "interventions": [
        {
          "name": "Tafenoquine Control",
          "type": "DRUG"
        },
        {
          "name": "Tafenoquine dissolution profile X",
          "type": "DRUG"
        },
        {
          "name": "Tafenoquine SIL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 14,
      "start_date": "2016-05",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2017-01-20",
      "last_synced_at": "2026-10-24T10:35:18.984Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02751294"
    },
    {
      "nct_id": "NCT02184637",
      "title": "A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria, Vivax"
      ],
      "interventions": [
        {
          "name": "Tafenoquine",
          "type": "DRUG"
        },
        {
          "name": "Dihydroartemisinin + Piperaquine tetraphosphate",
          "type": "DRUG"
        },
        {
          "name": "Artemether + Lumefantrine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 120,
      "start_date": "2014-07-31",
      "completion_date": "2015-04-08",
      "has_results": false,
      "last_update_posted_date": "2017-07-13",
      "last_synced_at": "2026-10-24T10:35:18.984Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02184637"
    },
    {
      "nct_id": "NCT02239614",
      "title": "TDENV PIV and LAV Dengue Prime-boost Strategy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "TDENV-LAV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TDENV-PIV 4 µg + alum adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 80,
      "start_date": "2014-12",
      "completion_date": "2017-02-17",
      "has_results": false,
      "last_update_posted_date": "2018-08-15",
      "last_synced_at": "2026-10-24T10:35:18.984Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02239614"
    },
    {
      "nct_id": "NCT00844207",
      "title": "A Phase 1 Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "Fixed combination of Azithromycin and Chloroquine",
          "type": "DRUG"
        },
        {
          "name": "Azithromycin and Chloroquine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2009-02",
      "completion_date": "2009-04",
      "has_results": false,
      "last_update_posted_date": "2009-04-21",
      "last_synced_at": "2026-10-24T10:35:18.984Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00844207"
    },
    {
      "nct_id": "NCT05043714",
      "title": "Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Cancer",
        "Epithelial Tumor"
      ],
      "interventions": [
        {
          "name": "NG-641 in combination with Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Akamis Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-12-01",
      "completion_date": "2024-10-04",
      "has_results": false,
      "last_update_posted_date": "2025-03-24",
      "last_synced_at": "2026-10-24T10:35:18.984Z",
      "location_count": 4,
      "location_summary": "Fullerton, California • Santa Monica, California • Celebration, Florida + 1 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Celebration",
          "state": "Florida"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05043714"
    },
    {
      "nct_id": "NCT05394064",
      "title": "A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "AMN",
        "AMN Gene Mutation",
        "X-ALD"
      ],
      "interventions": [
        {
          "name": "SBT101 Treatment",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "SwanBio Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 9,
      "start_date": "2022-11-17",
      "completion_date": "2025-08-31",
      "has_results": true,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-10-24T10:35:18.984Z",
      "location_count": 1,
      "location_summary": "Worcester, Massachusetts",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05394064"
    },
    {
      "nct_id": "NCT02766699",
      "title": "A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Astrocytoma, Grade IV"
      ],
      "interventions": [
        {
          "name": "EGFR(V)-EDV-Dox",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Engeneic Pty Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2016-10-25",
      "completion_date": "2022-03-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-03",
      "last_synced_at": "2026-10-24T10:35:18.984Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • New York, New York",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02766699"
    }
  ]
}